post broad-bas top bottom beat new patient commentari
particularli impress guidanc rais accordingli cgm market inflect
best product mix shift pharmaci ou continu
provid modest revenu per patient headwind still expect revenu upsid
view core long-term hold
revenu y/i beat forecast consensu
beat broad base us y/i ou y/i durabl
y/i sensor y/i revenu ahead expect manag note
us commerci patient pipelin doubl y/i page
gross margin came consensu though full year gross margin
guidanc reiter impli despit lower gross margin
oper margin beat forecast consensu rel
model sg primari upsid driver oper profit exceed forecast
revenu guidanc rais impli revenu
manag note assum revenu headwind increas
pharmaci channel mix cover live pharmaci coverag
increas revenu forecast still see room upsid
despit headwind pharmaci channel also increas revenu
forecast prior consensu
cgm market inflect benefit accur reliabl
product market remain ampl opportun growth us
type market like exit penetr ou still materi lower
minim intens manag type penetr though manag note improv
reimburs access take time also continu make progress
non-intens initi expect drive signific long-term revenu upsid
continu view core long-term hold price target base
dcf analysi impli publish revenu forecast p/fcf
lastli announc plan host investor event tuesday decemb
expect updat pipelin long-term revenu growth profit
pleas see page report import disclosur
believ make core growth stori attract
market dynam technolog differenti top-tier manag team
scalabl profit model competit potenti long-term price headwind
exist howev best pipelin industri expect remain clear
market leader forese futur wherev market goe
regulatori commerci mileston
us type cgm penetr continu
rapidli increas beyond
declin
cgm penetr continu rapidli
increas toward standard care us
cgm begin adopt
revenu growth sustain pace
thereaft
type penetr come faster
cgm penetr slow fail progress
toward standard care
price deterior faster expect
found headquart san diego california medic devic
compani focus design develop commerci continu glucos
monitor cgm system use peopl diabet use healthcar
provid hospit treatment patient without diabet dexcom
flagship offer today dexcom mobil patient diabet detect
trend track glucos pattern fda approv pediatr patient adult
move forward compani focus continu drive advanc cgm
technolog focus accuraci comfort connect longer term dexcom
goal replac tradit blood glucos monitor technolog
compani report thomson eikon cowen compani
cowen vs consensu mm except revenu metric mm except statement mm except per y/i nmnmnmnmshare count durabl revenu beat forecast grow y/i rel forecast beat driven primarili receiv revenu impli robust new patient start note new patient add y/i impli new patient start expect without pharmaci relat headwind beat would even sensor revenu beat forecast grow y/i manag note increas pharmaci channel mix provid headwind us revenu expect provid headwind sensor revenu continu grow corpor averag non-gaap ep came ahead expect exclud better expect non-oper expens lower expect tax rate ep would still well ahead revenu beat forecast consensu revenu growth come higher expect rel model beat broad base across us ou durabl sensor ou perform particularli impress ou revenu y/i huge gross margin forecast consensu said come similar guidance/manag commentari call continu pressur due launch strain organiz resourc full year guidanc expens came forecast though sg expens came forecast sale oper margin came well ahead expect oper profit came expect cowen
compani report thomson eikon cowen compani
mm except per share profit gener oper total opex y/i non-intens invest earn per consensu estim mm except per share gross op cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
medic suppli devic diabet
risk diabet devic sector may includ regulatori process potenti delay
commerci launch new product potenti price pressur payor/cm
premium rel valuat competit high level invest need compet
make invest recommend earli stage diabet devic compani base
upon assess technolog probabl market success competit
regulatori reimburs etc potenti market opportun event
success howev compani lack tradit and/or matur financi
metric believ specif methodolog assign price target
risk includ limit cgm penetr fail increas competit product
reduc competit moat profit push back materi new product
releas delay due regulatori hurdl trade signific premium
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen credit research trade due natur fix incom market issuer debt secur issuer discuss cowen credit research trade
research report assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon
analysi reflect analyst opinion date report expect continu analysi addit report relat issuer debt secur
time time cowen credit research trade research analyst provid invest recommend secur subject report
recommend intend time date public within paramet specifi individu report cowen credit research trade
invest recommend made strictli case-by-cas basi recommend provid part overarch rate system set consist
appli benchmark view express report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc novemb et dissemin novemb et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
